Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oncolytics Biotech Inc

0.3600
+0.02728.17%
Post-market: 0.3500-0.0100-2.78%19:47 EDT
Volume:684.71K
Turnover:233.81K
Market Cap:31.98M
PE:-1.29
High:0.3600
Open:0.3382
Low:0.3258
Close:0.3328
Loading ...

Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
21 May

Oncolytics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
17 May

Oncolytics Biotech (ONCY) was downgraded to a Hold Rating at JonesTrading

TIPRANKS
·
17 May

Oncolytics Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Oncolytics Biotech Q1 EPS $(0.06) Beats $(0.09) Estimate

Benzinga
·
15 May

Press Release: Oncolytics Biotech(R) Reports First Quarter Financial Results and Highlights Clinical Momentum

Dow Jones
·
15 May

Oncolytics Biotech Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
13 May

Oncolytics Biotech Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
05 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
02 May

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

PR Newswire
·
24 Apr

Press Release: Oncolytics Biotech(R) Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Dow Jones
·
11 Apr

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

PR Newswire
·
10 Apr

Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Mar

Oncolytics Biotech Is Maintained at Outperform by RBC Capital

Dow Jones
·
11 Mar

Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)

TIPRANKS
·
10 Mar

RBC Lowers Price Target on Oncolytics Biotech to CA$5 From CA$6, Keeps Outperform, Speculative Risk

MT Newswires Live
·
10 Mar

Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing

TIPRANKS
·
09 Mar

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

GuruFocus.com
·
08 Mar

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

MT Newswires
·
07 Mar

Oncolytics reports Q4 EPS (10c) vs. (5c) last year

TIPRANKS
·
07 Mar